Introduction {#tca12565-sec-0001}
============

Smetana *et al*. first described pulmonary mucoepidermoid carcinoma (PMEC) in 1952.[1](#tca12565-bib-0001){ref-type="ref"}, [2](#tca12565-bib-0002){ref-type="ref"}, [3](#tca12565-bib-0003){ref-type="ref"}, [4](#tca12565-bib-0004){ref-type="ref"} It is an extremely rare malignant neoplasm of the lung that accounts for approximately 0.1--0.2% of all lung malignancies.[3](#tca12565-bib-0003){ref-type="ref"}, [4](#tca12565-bib-0004){ref-type="ref"}, [5](#tca12565-bib-0005){ref-type="ref"}, [6](#tca12565-bib-0006){ref-type="ref"}, [7](#tca12565-bib-0007){ref-type="ref"} PMEC is a salivary gland‐type tumor of the lung,[5](#tca12565-bib-0005){ref-type="ref"}, [8](#tca12565-bib-0008){ref-type="ref"} deriving from the minor salivary glands of the tracheobronchial tree[9](#tca12565-bib-0009){ref-type="ref"} and has been reported to occur over an age range of 3--78 years.[3](#tca12565-bib-0003){ref-type="ref"}, [10](#tca12565-bib-0010){ref-type="ref"}, [11](#tca12565-bib-0011){ref-type="ref"} Compared to other salivary gland‐type tumors of the lung, there is no gender predilection in PMEC.[5](#tca12565-bib-0005){ref-type="ref"}, [12](#tca12565-bib-0012){ref-type="ref"} According to the 2015 World Health Organization classification of lung cancer, PMEC is a mucoepidermoid carcinoma.[13](#tca12565-bib-0013){ref-type="ref"} Histologically, PMEC consists of mucous‐forming, epidermoid, and intermediate cells that are divided into high‐grade and low‐grade variants.[2](#tca12565-bib-0002){ref-type="ref"}, [5](#tca12565-bib-0005){ref-type="ref"}, [8](#tca12565-bib-0008){ref-type="ref"}, [13](#tca12565-bib-0013){ref-type="ref"}, [14](#tca12565-bib-0014){ref-type="ref"}, [15](#tca12565-bib-0015){ref-type="ref"} As opposed to high‐grade PMEC, the prognosis of low‐grade PMEC is excellent, with very good five‐year survival rates.[16](#tca12565-bib-0016){ref-type="ref"}

Case Report {#tca12565-sec-0002}
===========

A 71‐year old man with a long smoking history presented for evaluation of an asymptomatic lung mass in the right upper lobe (Table [1](#tca12565-tbl-0001){ref-type="table-wrap"}, patient 1). On physical examination, his vital signs were normal and there were no abnormalities on auscultation of the chest. Enhanced chest computed tomography (CT) showed a solitary mass with heterogeneous enhancement in the apicoposterior segment of the upper lobe of the right lung (Fig [1](#tca12565-fig-0001){ref-type="fig"}a). Laboratory evaluation showed elevated carcinoembryonic antigen levels (5.86 μg/L; normal range 0--5 μg/L) but no other abnormalities. The patient underwent video‐assisted thoracic surgery with right upper lobectomy and lymph node dissection. Grossly, the mass measured 4 × 3.5 × 2.5 cm and was grey‐white in color. On microscopic examination, all three typical cell types of mucoepidermoid carcinoma were observed (Fig [2](#tca12565-fig-0002){ref-type="fig"}). Immunohistochemistry revealed that the tumor cells were diffusely positive for CK 7; partially positive for CK 5/6, p63, and TTF‐1; and negative for p40, NapsinA, SOX‐2, and SPA. Ki‐67 was approximately 70%. The final diagnosis was high‐grade PMEC with pleural and paratracheal lymph node invasion (T2aN1M0, stage II b). All resection margins were negative. Postoperative CT showed good recovery (Fig [1](#tca12565-fig-0001){ref-type="fig"}b). The patient had four cycles of postoperative adjuvant chemotherapy with paclitaxel and carboplatin, and there were no signs of relapse during 10 months of follow‐up.

###### 

Detailed clinical features of eight cases of surgically resected PMEC at our institution

  No.    Age   Gender   Smoking index    Symptom     Location       Location 2           Surgical procedure        Grade    pTNM    Adjuvant treatment   Outcome   OS (months)   DFS (months)
  ----- ----- -------- --------------- ------------ ---------- -------------------- ----------------------------- ------- -------- -------------------- --------- ------------- --------------
  1      71      M          2000           None        RUL      Segmental bronchus            Lobectomy            High    T2N1M0          Yes            Alive         9             9
  2      29      F            0          Dyspnea       RUL        Lobar bronchus          Sleeve lobectomy          Low    T1N0M0           No            Alive        77             77
  3      39      M           400        Hemoptysis   Trachea         Trachea         Sleeve resection of trachea    Low    T1N0M0           No            Alive        83             83
  4      74      M          1200           None        RLL      Segmental bronchus         Wedge resection          Low    T1N0M0          Yes            Alive        14             14
  5      69      F            0           Cough        RUL        Lobar bronchus          Sleeve lobectomy         High    T1N0M0           No            Alive         6             6
  6      76      M           800         Dyspnea       RUL        Lobar bronchus          Sleeve lobectomy         High    T4N1M0           No            Alive        17             14
  7      43      F            0           Cough        LUL        Lobar bronchus          Sleeve lobectomy          Low    T2N0M0           No            Alive        36             36
  8      39      M          1600          Cough        RUL        Lobar bronchus          Sleeve lobectomy          Low    T1N0M0           No            Alive        35             35

DFS, disease‐free‐survival; LUL, left upper lobe; OS, overall‐survival; PMEC, primary pulmonary mucoepidermoid carcinoma; pTNM, pathological tumor node metastasis; RLL, right lower lobe; RUL, right upper lobe.

![Chest computed tomography (CT) scans. (**a**) Enhanced CT shows a solitary mass with heterogeneous enhancement in the apico‐posterior segment of the upper lobe of the right lung, approximately 3.5 × 3.4 × 2.7 cm in size. (**b**) CT taken two months postoperatively shows good recovery.](TCA-9-316-g001){#tca12565-fig-0001}

![Hematoxylin--eosin (HE) staining and immunohistochemistry. The tumor cells were diffusely positive for CK 7; partially positive for CK 5/6, p63, and TTF‐1; and negative for p40, NapsinA, SOX‐2, and SPA.](TCA-9-316-g002){#tca12565-fig-0002}

Written informed consent was obtained from all patients for the publication of this case report and accompanying images.

Discussion {#tca12565-sec-0003}
==========

Several published reviews confirm that complete surgical resection remains the best treatment choice for PMEC and can result in better long‐term survival compared to non‐surgical treatment.[4](#tca12565-bib-0004){ref-type="ref"}, [5](#tca12565-bib-0005){ref-type="ref"}, [6](#tca12565-bib-0006){ref-type="ref"}, [12](#tca12565-bib-0012){ref-type="ref"} Advanced disease at the time of initial diagnosis may make complete resection difficult, especially in cases of high‐grade PMEC. Because PMEC is a type of non‐small cell lung cancer, adjuvant therapy should be administered when complete resection is not possible, although the utility of chemotherapy and radiotherapy in these cases remains controversial.[5](#tca12565-bib-0005){ref-type="ref"}, [6](#tca12565-bib-0006){ref-type="ref"}, [7](#tca12565-bib-0007){ref-type="ref"}, [14](#tca12565-bib-0014){ref-type="ref"}, [17](#tca12565-bib-0017){ref-type="ref"}, [18](#tca12565-bib-0018){ref-type="ref"}

We searched medical records from Tianjin Medical University General Hospital from January 2010 to April 2017 and identified a total of eight surgically resected cases of PMEC. Table [1](#tca12565-tbl-0001){ref-type="table-wrap"} displays the characteristics of the eight patients and the surgical results. Patient 6, who had advanced high‐grade disease (T4N1M0; stage IIIa) underwent extensive resection but refused chemotherapy, and experienced recurrence at 14 months. Patient 4, who had poor cardiovascular status, underwent a wedge resection with a final diagnosis of low‐grade PMEC with positive margins. Thus, he received two cycles of pemetrexed and nedaplatin and one cycle of gemcitabine and nedaplatin and showed no sign of relapse during 14 months of follow‐up.

In addition to our in‐house review, we reviewed 695 cases of PMEC from nine previous studies. Most PMECs are low/intermediate grade, and tumor locations indicate no particular tendency (Fig [3](#tca12565-fig-0003){ref-type="fig"}). Complete resection of PMEC, whether high‐grade or low‐grade, in the absence of lymph node metastasis, yielded good prognosis, and prognostic factors predicting aggressive behavior included age, histological grade, tumor‐node‐metastasis stage, lymph node metastasis, and complete resection (Table [2](#tca12565-tbl-0002){ref-type="table-wrap"}).

![Tumor localization in 695 patients with primary pulmonary mucoepidermoid carcinoma. Tumors had no particular location tendency and were distributed almost equally among the trachea, right main bronchus (RMB), left main bronchus (LMB), and all lobes of both lungs. Br, bronchus; LLL, LUL, left upper lobe; left lower lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.](TCA-9-316-g003){#tca12565-fig-0003}

###### 

Clinicopathological characteristics and outcomes of literature review

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                     Year (period)        Country           Number of cases                 Age (years)                   Gender (%)                 Size (cm)                  Treatment                TNM stage (%)            LN involvement (%)      Intrathoracic invasion (%)                 Survival data                             Prognostic factors
  ---------------------------------------------------------- ------------------- --------------- ---------------------------- ------------------------------ -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ---------------------------- -------------------------------------------- -------------------------------------------
  Jiang *et al.* [2](#tca12565-bib-0002){ref-type="ref"}      2014 (2001--2013)       China             34 (L 25, H 9)          H: Median age 65 (24--78)\          M 19 (44.1)\            H: 3.5 (1.5--5.0)\            Surgery 34\            H: I--IIA 3 (33.3)\          H: Yes 6 (66.7)\                   NA                            5 YSR OS 84.6%\                                   Age\
                                                                                                                                L: Median age 40 (16--76)           F 15 (55.9)             L: 2.5 (0.6--6.0)       Postoperative Treatment\      IIB--IV 6 (66.7)\             No 3 (33.3)\                                                   5 YSR DFS 81.6%                                TNM stage\
                                                                                                                                                                                                                        Radiotherapy 2\          L: I--IIA 22 (88.0)\         L: Yes 1 (4.0)\                                                                                                   Grade\
                                                                                                                                                                                                                         Chemotherapy 7            IIB--IV 3 (12.0)             No 24 (96.0)                                                                                                 LN metastasis

  Hsieh *et al.* [4](#tca12565-bib-0004){ref-type="ref"}            2017\            China\            41 (L 10, H 31)               ≤ 65 19 (46.3%)\               M 30 (73.2)\            ≤ 3 cm 25 (61.0%)\             Surgery 41                I 21 (51.2)\              Yes 15 (36.6)\                    NA                                 Stage\                                  Disease stage\
                                                                (1991--2015)        (Taiwan)                                         \> 65 22 (53.7%)               F 11 (26.8)             \> 3 cm 16 (39.0%)                                      II 11 (26.8)\               No 26 (63.4)                                                    I: 5 YSR 7.0%\                                pT status\
                                                                                                                                                                                                                                                   III--IV 9 (22.0)                                                                            II: 5 YSR 70.7%\                               pN status\
                                                                                                                                                                                                                                                                                                                                              III--IV: 5 YSR 0%\                                  ALI
                                                                                                                                                                                                                                                                                                                                                    Grade\                    
                                                                                                                                                                                                                                                                                                                                               L: 5 YSR 66.7%\                
                                                                                                                                                                                                                                                                                                                                                H: 5 YSR 53.2%                

  Zhu *et al.* [9](#tca12565-bib-0009){ref-type="ref"}              2014\             China          42 (L/INT 33, H 9)\         MAML2 rearrangement (+)\     MAML2 rearrangement (+)\   MAML2 rearrangement (+)\              NA              MAML2 rearrangement (+)\   MAML2 rearrangement (+)\    MAML2 rearrangement (+)\             MAML2 rearrangement (+)\                       MAML2 rearrangement
                                                                (2004--2011)                       MAML2 rearrangement (+)\      Median age 33 (14--73)\            M 13 (61.9)\             3.0 (0.5--6.5)\                                      I--IIA 19 (90.5)\             Yes 2 (9.5)\               Yes 4 (19.0)\                       5 YSR OS 94.7%\                
                                                                                                         (*n* = 21)\             MAML2 rearrangement (−)\           F 8 (38.1)\          MAML2 rearrangement (−)\                                  IIB--IV 2 (9.5)\            No 19 (90.5)\               No 17 (81.0)\                       5 YSR DFS 88.4%\               
                                                                                                   MAML2 rearrangement (−)\       Median age 60 (27--76)      MAML2 rearrangement (−)\       3.0 (0.5--10.0)                                   MAML2 rearrangement (−)\   MAML2 rearrangement (−)\    MAML2 rearrangement (−)\             MAML2 rearrangement (−)\           
                                                                                                          (*n* = 21)                                                M 12 (57.1)\                                                                  I--IIA 17 (81.0)\            Yes 5 (23.8)\               Yes 6 (28.6)\                       5 YSR OS 64.6%\                
                                                                                                                                                                     F 9 (48.3)                                                                    IIB--IV 2 (19.0)             No 16 (76.2)                No 15 (71.4)                       5 YSR DFS 53.0%                

  Huo *et al.* [10](#tca12565-bib-0010){ref-type="ref"}             2015\             China             26 (L 18, H 8)            Mean age 46.5 (12--79)            M 13 (50.0)\                    NA                    Surgery 23\                     NA                    Yes 1 (3.8)\                Yes 2 (7.7)\                    5 and 10 YSR OS 72.1%                                Age,\
                                                                (2000--2014)                                                                                        F 13 (50.0)                                          Chemotherapy 3                                        No 21 (80.8)\               No 20 (76.9)\                                                       peribronchial growth pattern, tumor size\
                                                                                                                                                                                                                                                                                NA 4 (15.4)                 NA 4 (15.4)                                                                         grade\
                                                                                                                                                                                                                                                                                                                                                                                         Ki‐67 labeling index

  Lee *et al.* [12](#tca12565-bib-0012){ref-type="ref"}             2014\             Korea         23 (L 5, INT 12, H 6)       H: Median age 57 (24--75)\          M 13 (56.5)\            H: 3.0 (2.0--4.0)\             Surgery 23             I--IIA 22 (95.7)\              Yes 0 (0)\                      NA                            5 YSR DFS 100%\                                    NA
                                                                (2000--2010)                                                   INT: Median age 32 (10--62)\         F 10 (43.5)           INT: 2.35 (1.0--3.0)\                                    IIB--IV 1 (4.3)\             No 23 (100)                                                     8 YSR OS 100%\                
                                                                                                                                L: Median age 32 (12--54)                                    L: 1.4 (0--3.7)                                          NA 2 (9.5)                                                                               8 YSR DFS 90.9%                

  Zhu *et al.* [14](#tca12565-bib-0014){ref-type="ref"}             2013\             China        69 (L 45, INT 11, H 13)       Median age 47.5 (7--73)            M 38 (55.1)\              2.65 (0.5--10)              Surgery 66\                I 48 (69.6)\              Yes 12 (17.6)\              Yes 16 (23.1)\                           Stage\                                    TNM stage,\
                                                                (2001--2013)                                                                                        F 31 (44.9)                                         Chemotherapy 3\             II 12 (17.4)\               No 57 (82.6)                No 53 (76.8)                     I--IIA: 5 YSR 90.8%\                      intrathoracic invasion,\
                                                                                                                                                                                                                         Radiotherapy 4             III 8 (11.6)\                                                                            IIB--IV: 5 YSR 54%\                            LN metastasis,\
                                                                                                                                                                                                                                                      IV 1 (1.4)                                                                                    Grade\                                   margin status
                                                                                                                                                                                                                                                                                                                                              L‐INT: 5 YSR 95%\               
                                                                                                                                                                                                                                                                                                                                                H: 5 YSR 41.7%                

  Komiya *et al.* [16](#tca12565-bib-0016){ref-type="ref"}          2016\         United States              423\                   ≥ 39 130 (30.7%)\              M 232 (54.8)\                    NA                 Surgery alone 274\                 NA                         NA                          NA                                 Stage\                                       Age,\
                                                                (1973--2012)                      (L 226, H 73, unknown 124)       40--69 219 (51.8%)\              F 191 (45.2)                                    Surgery + Radiation 30\                                                                                                 Localized: 5 YSR 97%\                           distant stage,\
                                                                                                                                     ≥ 70 74 (17.5%)                                                                  Radiation alone 64\                                                                                                   Regional: 5 YSR 56.9%\                               grade
                                                                                                                                                                                                                           Neither 55                                                                                                        Distant: 5 YSR 8.2%\             
                                                                                                                                                                                                                                                                                                                                                    Grade\                    
                                                                                                                                                                                                                                                                                                                                               L: 5 YSR 90.6%\                
                                                                                                                                                                                                                                                                                                                                                H: 5 YSR 28.6%                

  Salem *et al.* [20](#tca12565-bib-0020){ref-type="ref"}           2017          United States         16 (L 14, H 2)         Median age 40.4 (7.4--82.9)          M 7 (43.6)\             Median tumor size\            Surgery 14\               II 10 (62.4)\              Yes 3 (18.8)\                Yes 1 (6.3)\          Median follow‐up months 40.7 (1.7--120.1)\  
                                                                                                                                                                     F 9 (56.3)               2.6 (0.6--10)               Radiation 6\              III 3 (18.8)\               No 13 (81.2)                No 15 (93.7)                        Died 3 (18.8)\                
                                                                                                                                                                                                                         Chemotherapy 3              IV 3 (18.8)                                                                               Alive 13 (81.2)                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALI, angiolymphatic invasion; H, high‐grade tumors; INT, intermediate‐grade tumors; L, low‐grade tumors; LN, lymph node; NA, not assessed; PMEC, primary pulmonary mucoepidermoid carcinoma; TNM, tumor node metastasis; YSR, year survival rate.

The *MECT1/3* fusion gene is common in PMEC.[8](#tca12565-bib-0008){ref-type="ref"}, [9](#tca12565-bib-0009){ref-type="ref"}, [10](#tca12565-bib-0010){ref-type="ref"} In 62 patients analyzed in our systemic review, *MAML2* rearrangement was much more common in low‐grade (73.9%) compared to high‐grade (18.8%) PMEC cases (Table [3](#tca12565-tbl-0003){ref-type="table-wrap"}). Five‐year overall survival was also better in the *MAML2* rearrangement‐positive group (94.7% vs. 64.6% in patients without *MAML2* rearrangement). Thus, *MAML2* rearrangement may signal a better prognosis in cases of PMEC.

###### 

Summary of molecular analyses of PMECs from previous studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                    Year (period)  Country          Number of cases      Age (years)                  Sex (%)                    Size (cm)                  TNM stage (%)              LN involvement (%)         Intrathoracic invasion (%)   MAML2 rearrangement   EGFR mutation   Outcome
  ----------------------------------------------------------- --------------- ---------------- -------------------- ---------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ---------------------------- --------------------- --------------- --------------------------
  Behboudi *et al.* [8](#tca12565-bib-0008){ref-type="ref"}        2006       Sweden\          Case 1: L\           Case 1: 6\                   Case 1: F\                 Case 1: 1.3\               NA                         NA                         NA                           Case 1: Positive\     NA              Case 1: 14 years\
                                                                              Finland          Case 2: L\           Case 2: 35\                  Case 2: M\                 Case 2: 1.0\                                                                                                  Case 2: Positive\                     Case 2: 11 years\
                                                                                               Case 3: L            Case 3: 32                   Case 3: F                  Case 3: NA                                                                                                    Case 3: Positive                      Case 3: 5 years

  Zhu *et al.* [9](#tca12565-bib-0009){ref-type="ref"}             2014\      China            42 (L/INT 33, H 9)   MAML2 rearrangement (+)\     MAML2 rearrangement (+)\   MAML2 rearrangement (+)\   MAML2 rearrangement (+)\   MAML2 rearrangement (+)\   MAML2 rearrangement (+)\     Positive 21\          NA              MAML2 rearrangement (+)\
                                                               (2004--2011)                                         Median age 33 (14--73)\      M 13 (61.9)\               3.0 (0.5--6.5)\            I--IIA 19 (90.5)\          Yes 2 (9.5)\               Yes 4 (19.0)\                L/INT 21\                             5 YSR OS 94.7%\
                                                                                                                    MAML2 rearrangement (−)\     F 8 (38.1)\                MAML2 rearrangement (−)\   IIB--IV 2 (9.5)\           No 19 (90.5)\              No 17 (81.0)\                H 0\                                  5 YSR DFS 88.4%\
                                                                                                                    Median age 60 (27--76)       MAML2 rearrangement (−)\   3.0 (0.5--10.0)            MAML2 rearrangement (−)\   MAML2 rearrangement (−)\   MAML2 rearrangement (−)\     Negative 21\                          MAML2 rearrangement (−)\
                                                                                                                                                 M 12 (57.1)\                                          I--IIA 17 (81.0)\          Yes 5 (23.8)\              Yes 6 (28.6)\                L/INT 12\                             5 YSR OS 64.6%\
                                                                                                                                                 F 9 (48.3)                                            IIB--IV 2 (19.0)           No 16 (76.2)               No 15 (71.4)                 H 9                                   5 YSR DFS 53.0%

  Achcar *et al.* [21](#tca12565-bib-0021){ref-type="ref"}         2009\      United Kingdom   17 (L 10, H 7)       MAML2 rearrangement (+)\     MAML2 rearrangement (+)\   NA                         NA                         NA                         NA                           Positive 13\          NA              NA
                                                               (1997--2008)                                         Median age 39.5 (33--51)\    M 2 (15.4)\                                                                                                                              L 10\                                 
                                                                                                                    MAML2 rearrangement (−)\     F 11 (84.6)\                                                                                                                             H 3\                                  
                                                                                                                    Median age 59 (23--82)       MAML2 rearrangement (−)\                                                                                                                 Negative 4\                           
                                                                                                                                                 M 3 (75.0)\                                                                                                                              L 0\                                  
                                                                                                                                                 F 1 (25.0)                                                                                                                               H 4                                   

  Yu *et al.* [22](#tca12565-bib-0022){ref-type="ref"}             2012\      China            20 (L 17, H 3)       H: Median age 65 (25--74)\   M 11 (55.0)\               H: 2.4 (1.5--3.5)\         NA                         NA                         NA                           NA                    L861Q 5\        Recurrence: L861Q 1\
                                                               (2001--2009)                                         L: Median age 48 (8--73)     F 9 (45.0)                 L: 2.1 (0.5--4.5)                                                                                                                   I760I 1\        I760I 0\
                                                                                                                                                                                                                                                                                                                None 14         None 1
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

H, high‐grade tumors; INT, intermediate‐grade tumors; L, low‐grade tumors; LN, lymph node; NA, not assessed; PMEC, primary pulmonary mucoepidermoid carcinoma; TNM, tumor‐node‐metastasis; YSR, year survival rate.

Finally, in a study by Han *et al.*, gefitinib administration was attempted to treat a case of PMEC after metastasis to the chest wall and contralateral lung.[8](#tca12565-bib-0008){ref-type="ref"}, [19](#tca12565-bib-0019){ref-type="ref"} CT follow‐up indicated that the metastatic lesions had responded to the treatment, although there was no *EGFR* tyrosine kinase mutation detected in the chest wall tumor. These findings suggest that PMECs with the *MECT1‐MAML2* fusion gene may be a valid target for tyrosine kinase inhibitor therapy. However, this hypothesis requires further investigation in a clinical setting.

In summary, complete surgical resection remains the mainstay of treatment for PMEC and can result in long‐term survival. Adjuvant chemotherapy may be useful in patients with high‐grade PMEC, especially in cases of lymph node involvement or intrathoracic invasion. The current literature indicates that the *MECT1‐MAML2* fusion gene is common in PMEC and is specific to this tumor. Identifying *MAML2* rearrangement might be helpful to differentiate PMEC from other epithelial lung malignancies. *MAML2* rearrangement seems to be associated with a favorable clinical outcome and PMEC cases with the *MECT1‐MAML2* fusion gene may exhibit a good response to tyrosine kinase inhibitor therapy.
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